



#10
4-11-01
P.2

PATENT
ATTORNEY DOCKET NO.: 98-4
Customer No.: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:)
MELIEF, Cornelis, et al.)
Serial No.: 09/316,935) Group Art Unit: 1632
Filed: May 22, 1999) Examiner: A. Beckerleg
For: CD40 BINDING MOLECULES AND CTL)
PEPTIDES FOR TREATING TUMORS)
Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO SEQUENCE LISTING REQUIRMENTS

In compliance with the Sequence Listing requirements, Applicants submit a substitute Sequence Listing and CRF diskette.

I hereby state that the amendments, made in accordance with 37 CFR 1.825(a), included in the substitute sheets of the Sequence Listing are supported in the application, as filed, at page 6, line 5 (SEQ ID NO 1), and page 4, lines 11-12 (SEQ ID Nos 2 and 3). I hereby state that the substitute sheets of the Sequence Listing do not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

In view of this substitution, Applicants are in compliance with all rules related to protein sequences.

Respectfully Submitted,

Dated: April 3, 2001.

BY:

Cheryl A. Liljestrand
Cheryl A. Liljestrand
Reg. No. 45,275

Mailing Address:

Tanox, Inc.
10301 Stella Link Rd
Houston, TX 77025
(713) 578-4000